Smartinhaler developer Nexus6 has raised NZ$1.6 million (US$1.34 million) from existing investors plus NZ$3 (US$2.5 million) from BioScience Managers, with additional funding expected to bring the total to NZ$5 million by the close of the round in March. The company says it will use the money to expand global sales and marketing of the Smartinhaler range of inhaler monitoring devices.
Nexus6 Founder Garth Sutherland said, “Smartinhaler represents a new paradigm in the management of asthma and respiratory diseases. We now have the resources to take this product to the world and continue to build Nexus6 into an international leader in remote patient monitoring solutions.”
The company also announced that David Bone, David Evans, Iain McCormick and Dennis Row are leaving the board of directors, with Doug Wilson (Chair), Jeremy Curnock Cook, Matt McNamara, Maxine Simmons, and Garth Sutherland remaining on the board.
Read the Nexus6 press release.
